| Withdrawn | Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC NCT06592664 | Lisata Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX C NCT07409272 | Astellas Pharma Global Development, Inc. | Phase 3 |
| Not Yet Recruiting | Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Canc NCT04901741 | TME Pharma AG | Phase 2 |
| Recruiting | The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic NCT06861088 | Quercis Pharma AG | Phase 3 |
| Not Yet Recruiting | Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Can NCT07262567 | Genfleet Therapeutics (Shanghai) Inc. | Phase 3 |
| Withdrawn | A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer NCT07026916 | Genfleet Therapeutics (Shanghai) Inc. | Phase 2 |
| Recruiting | The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation NCT06843551 | Benjamin Spieler | Phase 2 |
| Recruiting | Alpha Radiation Emitters Device (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic NCT06698458 | Alpha Tau Medical LTD. | N/A |
| Recruiting | QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer NCT06951997 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel NCT06483555 | UNC Lineberger Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Recruiting | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab NCT06782555 | ImmunoGenesis | Phase 1 / Phase 2 |
| Recruiting | mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer NCT06761027 | Fujian Provincial Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer NCT06662669 | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effect NCT06688240 | Servier (Tianjin) Pharmaceutical Co. LTD. | — |
| Not Yet Recruiting | Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA NCT06621095 | RenJi Hospital | Phase 2 |
| Recruiting | A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors NCT06533332 | EtiraRx Australia Pty Ltd | Phase 1 |
| Recruiting | Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcit NCT06454448 | Tianjin Medical University Cancer Institute and Hospital | Phase 1 / Phase 2 |
| Recruiting | A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclit NCT06361888 | Hutchmed | Phase 2 / Phase 3 |
| Active Not Recruiting | Proglumide and Chemotherapy for Metastatic Pancreatic Cancer NCT05827055 | Georgetown University | Phase 2 |
| Recruiting | Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Ad NCT05988814 | Centre Georges Francois Leclerc | Phase 2 |
| Terminated | A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic NCT06199466 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With M NCT05927142 | Joachim Aerts, MD PhD | Phase 1 / Phase 2 |
| Withdrawn | Study of OB-002 in Patients With Refractory Metastatic Cancer NCT05940844 | Orion Biotechnology Polska Sp. z o.o. | Phase 1 |
| Active Not Recruiting | A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard NCT06532331 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer NCT06168812 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | An Observational Study to Learn More About the Impact of Gadoxetate Sodium-Enhanced Magnetic Resonance Imaging NCT06106568 | Bayer | — |
| Withdrawn | Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma NCT06017323 | Georgetown University | Phase 1 |
| Active Not Recruiting | Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With P NCT06059001 | Peptomyc S.L. | Phase 1 |
| Recruiting | Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer P NCT05929885 | National Cancer Centre, Singapore | Phase 2 |
| Recruiting | Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer NCT06018896 | Fudan University | Phase 2 |
| Recruiting | A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Advance NCT05657743 | Alpha Tau Medical LTD. | N/A |
| Recruiting | Olaparib in PALB2 Advanced Pancreatic Cancer NCT06078787 | Azienda Ospedaliero-Universitaria di Modena | Phase 2 |
| Recruiting | Implantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma NCT05869474 | Changhai Hospital | N/A |
| Recruiting | Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer NCT05766748 | Cantex Pharmaceuticals | Phase 1 / Phase 2 |
| Active Not Recruiting | Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy NCT07122466 | Northwell Health | — |
| Withdrawn | Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer NCT05634525 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Anamorelin Study for Advanced Pancreatic Cancer NCT04844970 | Lahey Clinic | Phase 2 |
| Withdrawn | PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers NCT05737615 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) NCT05642962 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes A NCT05659914 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Phase 2 |
| Terminated | Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer NCT05442749 | Centre Leon Berard | Phase 2 |
| Completed | A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer NCT05586516 | iOnctura | Phase 1 / Phase 2 |
| Withdrawn | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer NCT05251038 | Devalingam Mahalingam | Phase 1 / Phase 2 |
| Terminated | FOLFIRINOX + NIS793 in Pancreatic Cancer NCT05417386 | Colin D. Weekes, M.D., PhD | Phase 1 |
| Completed | A Study to Investigate 14C-bemcentinib in Healthy Male Subjects NCT06469138 | BerGenBio ASA | Phase 1 |
| Recruiting | Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients NCT05380414 | Centre Leon Berard | N/A |
| Withdrawn | Quality of Life With Nutritional Supplementation in Patients With Locally Advanced/Metastatic Pancreatic Cance NCT05360745 | Fundacion para la Excelencia y la Calidad de la Oncologia | N/A |
| Recruiting | Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC) NCT05346536 | University Hospital, Montpellier | N/A |
| Unknown | Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcin NCT05363007 | National Taiwan University Hospital | Phase 2 |
| Active Not Recruiting | Redefining FOLFIORINOX in Older Pancreatic Cancer Patients NCT05360732 | Fox Chase Cancer Center | Phase 2 |
| Active Not Recruiting | The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreate NCT05042128 | Australasian Gastro-Intestinal Trials Group | Phase 2 |
| Recruiting | Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC NCT04605913 | Mayo Clinic | Phase 1 / Phase 2 |
| Unknown | Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancre NCT06353581 | Yonsei University | Phase 2 |
| Recruiting | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzu NCT05143970 | Institut Paoli-Calmettes | Phase 1 |
| Recruiting | Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer NCT05065801 | Institut du Cancer de Montpellier - Val d'Aurelle | Phase 2 |
| Unknown | A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With N NCT05138159 | Fudan University | Phase 2 |
| Active Not Recruiting | Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer NCT04820179 | University of Arizona | Phase 2 |
| Recruiting | Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cance NCT04753879 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial) NCT05650918 | Joachim Aerts, MD PhD | Phase 1 |
| Active Not Recruiting | An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, th NCT06532344 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation NCT04327986 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Liver Embolization Approaches for Tumor Management NCT05714124 | IRCCS San Raffaele | — |
| Unknown | Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer NCT04718701 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Completed | Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab NCT04790695 | Ottawa Hospital Research Institute | Phase 2 |
| Completed | Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN) NCT04769414 | Menoufia University | Phase 2 |
| Completed | Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX t NCT04789980 | Boryung Pharmaceutical Co., Ltd | — |
| Completed | An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFI NCT06538207 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells NCT04150042 | General Oncology, Inc. | Phase 1 |
| Active Not Recruiting | Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer NCT04672005 | Lyudmyla Berim | Phase 2 |
| Recruiting | First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer NCT04665947 | University of California, Davis | EARLY_Phase 1 |
| Completed | Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer NCT04177810 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Recruiting | Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors NCT04222413 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Saltikva for Metastatic Pancreatic Cancer NCT04589234 | Salspera LLC | Phase 2 |
| Active Not Recruiting | Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer NCT04002479 | Alpha Tau Medical LTD. | N/A |
| Unknown | PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Met NCT04612530 | Amsterdam UMC, location VUmc | Phase 1 |
| Terminated | A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has No NCT04300114 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Completed | Niraparib + Dostarlimab + RT in Pancreatic Cancer NCT04409002 | Massachusetts General Hospital | Phase 2 |
| Terminated | Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer. NCT04212026 | University Hospital, Basel, Switzerland | Phase 2 |
| Active Not Recruiting | Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer NCT04361162 | Massachusetts General Hospital | Phase 2 |
| Completed | A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer NCT04229004 | Pancreatic Cancer Action Network | Phase 3 |
| Unknown | Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer NCT03986294 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 2 |
| Terminated | Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabi NCT03714555 | HonorHealth Research Institute | Phase 2 |
| Unknown | Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen NCT04101929 | Fudan University | Phase 2 |
| Completed | Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer NCT04133155 | Asan Medical Center | — |
| Unknown | Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Ca NCT04498689 | Fudan University | Phase 2 |
| Unknown | Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Effica NCT03666832 | Joon Oh Park | Phase 1 / Phase 2 |
| Terminated | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma NCT03785210 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Multimodal Managements for Metastatic Pancreatic Cancer. NCT06967233 | Zhejiang University | — |
| Withdrawn | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) NCT03697239 | Hitendra Patel | Phase 1 / Phase 2 |
| Withdrawn | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) NCT03908333 | Medical College of Wisconsin | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer NCT03816163 | Astellas Pharma Global Development, Inc. | Phase 2 |
| Unknown | Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresect NCT04112836 | Moscow Clinical Scientific Center | — |
| Unknown | Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer NCT03929094 | Fudan University | Phase 2 |
| Completed | Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity NCT03821870 | Vejle Hospital | — |
| Unknown | First-line Therapy in Metastatic PDAC NCT03487016 | Ludwig-Maximilians - University of Munich | Phase 2 |
| Recruiting | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors NCT03682289 | Rahul Aggarwal | Phase 2 |
| Withdrawn | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) NCT03797443 | Piedmont Cancer Institute | Phase 1 / Phase 2 |
| Completed | First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen o NCT03693677 | Federation Francophone de Cancerologie Digestive | Phase 2 |
| Recruiting | A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Ca NCT03721744 | 1Globe Health Institute LLC | Phase 2 / Phase 3 |
| Completed | EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options NCT03602885 | Dana-Farber Cancer Institute | N/A |
| Terminated | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma NCT03376659 | Georgetown University | Phase 1 / Phase 2 |
| Withdrawn | QUILT-3.088: NANT Pancreatic Cancer Vaccine NCT03563144 | ImmunityBio, Inc. | Phase 2 |
| Unknown | Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer NCT03502343 | Yonsei University | Phase 2 |
| Completed | 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Th NCT03468335 | AIO-Studien-gGmbH | Phase 3 |
| Completed | Post Marketing Surveillance Study for ONIVYDE® in South Korea NCT03446872 | Institut de Recherches Internationales Servier | — |
| Completed | A Study of ASN007 in Patients With Advanced Solid Tumors NCT03415126 | Asana BioSciences | Phase 1 |
| Completed | A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic NCT03331562 | Translational Genomics Research Institute | Phase 2 |
| Completed | A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable NCT03250273 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreat NCT03261947 | Millennium Pharmaceuticals, Inc. | Phase 2 |
| Unknown | A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Can NCT03435289 | Atlantic Health System | Phase 1 |
| Completed | RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer NCT03189914 | Processa Pharmaceuticals | Phase 1 / Phase 2 |
| Terminated | Relationship Between Evolution of Resting Energy Expenditure and Tumoral Response to Chemotherapy in Patients NCT02921646 | Center Eugene Marquis | N/A |
| Completed | Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer NCT03281382 | Henry Ford Health System | Phase 1 |
| Completed | A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastat NCT03086369 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Completed | Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer NCT03168139 | TME Pharma AG | Phase 1 / Phase 2 |
| Completed | First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine NCT02564146 | AIO-Studien-gGmbH | Phase 2 |
| Completed | Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cance NCT02866383 | Herlev Hospital | Phase 2 |
| Withdrawn | Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer NCT02967770 | Georgetown University | Phase 2 |
| Unknown | Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer NCT02975141 | PD Dr. med. Volker Heinemann | Phase 1 |
| Completed | Patient Reported Outcomes Registry in Patient With Cancer Cachexia NCT02983500 | iOMEDICO AG | — |
| Unknown | A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancrea NCT02863367 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Completed | A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cance NCT02734160 | Eli Lilly and Company | Phase 1 |
| Completed | Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer NCT02697058 | Institut de Recherches Internationales Servier | Phase 2 |
| Unknown | Project Survival-Prospective Biomarker Discovery NCT02781012 | Pancreatic Cancer Research Team | — |
| Terminated | Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With C NCT02404363 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab NCT02827201 | Federation Francophone de Cancerologie Digestive | Phase 2 |
| Terminated | Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreat NCT02570711 | Acerta Pharma BV | Phase 2 |
| Completed | Improving Informed Consent for Palliative Chemotherapy NCT02282722 | Dana-Farber Cancer Institute | N/A |
| Completed | Treatment of Pancreatic Cancer With Abraxane NCT02555813 | Celgene | — |
| Completed | ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer NCT02362048 | Acerta Pharma BV | Phase 2 |
| Completed | First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem NCT02352337 | Federation Francophone de Cancerologie Digestive | Phase 2 |
| Active Not Recruiting | Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer NCT02340117 | SynerGene Therapeutics, Inc. | Phase 2 |
| Completed | BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer NCT03627390 | Meabco A/S | Phase 2 |
| Completed | Observational Study on Quality of Life of Patients Receiving Nab-paclitaxel/Gemcitabine First Line Therapy, In NCT02691052 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | — |
| Unknown | Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer NCT02184663 | GERCOR - Multidisciplinary Oncology Cooperative Group | N/A |
| Completed | Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer P NCT02707159 | Helse Stavanger HF | Phase 2 |
| Completed | BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Tria NCT02080221 | Brown University | Phase 2 |
| Completed | Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreat NCT02077881 | NewLink Genetics Corporation | Phase 1 / Phase 2 |
| Withdrawn | Feasibility of Biodynamic Imaging for Predicting Therapeutic Effect in Metastatic Adenocarcinoma of the Pancre NCT02205788 | Patrick Joseph Loehrer Sr. | — |
| Unknown | Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer NCT01934634 | US Oncology Research | Phase 1 |
| Completed | Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as NCT02109341 | Gruppo Oncologico Italiano di Ricerca Clinica | Phase 1 / Phase 2 |
| Unknown | Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic C NCT01964534 | GERCOR - Multidisciplinary Oncology Cooperative Group | Phase 2 |
| Completed | Gemcitabine and Nabpaclitaxel in Metastatic Pancreatic Carcinoma. NCT03620461 | Galician Research Group on Digestive Tumors | — |
| Terminated | Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic C NCT01956812 | Gilead Sciences | Phase 3 |
| Terminated | Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer NCT01946646 | National Taiwan University Hospital | Phase 1 |
| Completed | PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants Wit NCT01839487 | Halozyme Therapeutics | Phase 2 |
| Completed | Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adeno NCT01764477 | Prism Pharma Co., Ltd. | Phase 1 |
| Completed | mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer NCT02028806 | Yuhong Li | Phase 2 |
| Unknown | QYHJ Granules Versus Xeloda in Metastatic Pancreatic Cancer NCT01796782 | Fudan University | Phase 2 |
| Completed | BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study NCT01744353 | Brown University | Phase 1 |
| Completed | BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer NCT01571024 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Terminated | M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer NCT01621243 | Momenta Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Withdrawn | A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Th NCT01510561 | Gilead Sciences | Phase 1 |
| Completed | QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer NCT01040000 | Precision Biologics, Inc | Phase 1 / Phase 2 |
| Unknown | A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Ge NCT01509911 | Tiltan Pharma Ltd. | Phase 2 |
| Withdrawn | Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1 NCT01524575 | University of Hawaii | Phase 2 |
| Completed | Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer NCT01494506 | Merrimack Pharmaceuticals | Phase 3 |
| Terminated | Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in M NCT01461915 | Jazz Pharmaceuticals | Phase 2 |
| Completed | Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer NCT01523457 | Yale University | Phase 2 |
| Completed | Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer NCT01417000 | Aduro Biotech, Inc. | Phase 2 |
| Completed | A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients Wi NCT01410968 | Carolyn Britten | Phase 1 |
| Completed | QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas NCT01231347 | NantCell, Inc. | Phase 3 |
| Completed | Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With NCT01303029 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Phase 2 |
| Completed | ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer NCT01489865 | Georgetown University | Phase 1 / Phase 2 |
| Completed | Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Can NCT01272791 | Peregrine Pharmaceuticals | Phase 2 |
| Completed | Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas NCT01088815 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Recruiting | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer NCT01174121 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Metformin Combined With Chemotherapy for Pancreatic Cancer NCT01210911 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 2 |
| Completed | A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer NCT01130142 | Infinity Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Unknown | A Study to Assess PV-10 Chemoablation of Cancer of the Liver NCT00986661 | Provectus Biopharmaceuticals, Inc. | Phase 1 |
| Completed | Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer NCT01077986 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 1 / Phase 2 |
| Completed | Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer NCT00954525 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |
| Completed | Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer NCT00922896 | Gyeongsang National University Hospital | Phase 2 |
| Completed | A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer NCT01028495 | Rexahn Pharmaceuticals, Inc. | Phase 2 |
| Completed | Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenoca NCT00844649 | Celgene | Phase 3 |
| Completed | Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas NCT00837031 | SCRI Development Innovations, LLC | Phase 2 |
| Terminated | A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Canc NCT00726037 | Loyola University | Phase 2 |
| Completed | Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer NCT00761345 | Fox Chase Cancer Center | Phase 1 |
| Completed | APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer NCT00709826 | Tragara Pharmaceuticals, Inc. | Phase 2 |
| Completed | QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancrea NCT00630552 | NantCell, Inc. | Phase 1 / Phase 2 |
| Completed | Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer NCT00786006 | Asan Medical Center | Phase 2 |
| Terminated | BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer NCT00447122 | Brown University | Phase 1 |
| Completed | A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer NCT00383149 | R-Pharm | Phase 2 |
| Completed | Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer NCT00398086 | Celgene | Phase 1 / Phase 2 |
| Completed | A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema NCT00439179 | Brown University | Phase 1 |
| Terminated | Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer NCT00868114 | Leo W. Jenkins Cancer Center | Phase 2 |
| Terminated | Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer NCT00326911 | Eli Lilly and Company | Phase 2 |
| Completed | Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma NCT00744640 | University Hospital, Basel, Switzerland | Phase 1 / Phase 2 |
| Completed | Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer NCT00222469 | University of Oklahoma | Phase 2 |
| Unknown | The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib NCT01608841 | Taipei Veterans General Hospital, Taiwan | Phase 2 |
| Completed | Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer NCT00652054 | Taiho Oncology, Inc. | Phase 2 |
| Completed | Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB) NCT00996333 | Columbia University | Phase 2 |
| Completed | A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer NCT00245362 | Cell Genesys | Phase 2 |
| Completed | Gemcitabine (GFF) in Patients With Pancreatic Cancer NCT00919282 | CONKO-Studiengruppe | Phase 2 |